Named a “Disruptor” and a “Rising Star” in her industry by PM360 and the Healthcare Business Women’s Association, Meg Alexander is a communications consultant on the speed-dials of countless healthcare C-Suite executives. Known for championing and protecting the interests of clients that may face policymaker scrutiny, media investigations and activist campaigns, Meg believes—and has shown—75% of issues can be predicted and mitigated when corporations are ‘tuned’ to the right signals.
For nearly a decade and a half, Meg has been helping Fortune 500 companies successfully navigate the most challenging issues facing their industries including drug pricing, product recalls, compassionate use campaigns, lawsuits, activist attacks and much more. In her role leading INC Research/inVentiv Health Public Relations Reputation and Risk Management Practice, she created award-winning corporate reputation and issues management strategies for iconic brands including: Pfizer, Novartis, Amgen, Johnson & Johnson, Boehringer Ingelheim, Lilly, Coca-Cola, Nestle, and Gerber, among others.
Meg is passionate about enhancing and protecting the reputation of businesses and their leaders in a complex, evolving healthcare landscape. She has been a go-to resource among her peers, and is widely published on healthcare communications best practices.
Meg has presented her perspectives at a number of leading industry forums, including BIO International 2016, PRSA International Conference, the Healthcare Business Women’s Association Annual Meeting, and BIO NJ. She is widely published on the topic of drug pricing, including: PHARMACEUTICAL EXECUTIVE: Pushback on Rare Drug Prices; Not So Rare Afterall; PM 360 Avoiding the Pricing Crisis; PHARMACEUTICAL EXECUTIVE: Navigating Post Turing: Defining Value in Today’s Landscape.